Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18302412 | 0.85 | TDP1 (0.57) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL23111329 | 0.85 | TDP1 (0.57) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL996633 | 0.82 | KDM4E (0.51) | SMN1; SMN2TDP1MAPTLIN28AALDH1A1 | |
| Acetaldehyde SCHEMBL27331159 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL16899929 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL13960891 | 0.80 | TDP1 (0.52) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL5563786 | 0.79 | TDP1 (0.50) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL10127312 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL5563789 | 0.79 | TDP1 (0.50) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL12903540 | 0.79 | MAPT (0.50) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | claimed |
| US-5663168-A | ADMINISTERING INHIBITORS OF HIV ASPARATATE PROTEASES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0560268-B1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-01-04 | — | — | EP | claimed |
| EP-0626178-A1 | Use of inhibitors of HIV-protease for the treatment of tumorous diseases | CIBA-GEIGY AG (CH) | 1994-11-30 | — | — | EP | claimed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | claimed |
| WO-1993018003-A1 | SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560268-A1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| WO-1993013066-A1 | CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-07-08 | — | — | WO | claimed |
| EP-0532466-A2 | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | claimed |
| WO-1992017176-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1992-10-15 | — | — | WO | claimed |
| US-5151438-A | Enzyme inhibitors for treatment of aids | ABBOTT LABORATORIES (US) | 1992-09-29 | — | — | US | claimed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2852596-B1 | THIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| EP-0560268-A1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| WO-1993013066-A1 | CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0532466-A2 | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133425-A1 | THIENOPYRIMIDINES | TYMP, DPYD, TYMS | SMN1; SMN2 1664/4885TDP1 185/4885MAPT 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.